Grisham, Rachel N <br/><br/>
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.  [electronic resource] 

 -  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society  Jul 2014 
 - 1010-4 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1525-1438 
<br/><br/><label>Standard No.: </label>10.1097/IGC.0000000000000190  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Carboplatin--administration & dosage<br/>Carcinoma, Ovarian Epithelial<br/>Cyclophosphamide--administration & dosage<br/>Cystadenocarcinoma, Serous--drug therapy<br/>Deoxycytidine--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Middle Aged<br/>Neoplasm Grading<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasm Staging<br/>Neoplasms, Glandular and Epithelial--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Paclitaxel--administration & dosage<br/>Peritoneal Neoplasms--drug therapy<br/>Prognosis<br/>Retrospective Studies<br/>Survival Rate<br/>Topotecan--administration & dosage<br/>Young Adult<br/>Gemcitabine